Maryland State Retirement & Pension System Lowers Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Maryland State Retirement & Pension System decreased its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 13.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,094 shares of the specialty pharmaceutical company’s stock after selling 2,514 shares during the quarter. Maryland State Retirement & Pension System’s holdings in Supernus Pharmaceuticals were worth $527,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Vident Advisory LLC raised its stake in Supernus Pharmaceuticals by 2.2% during the fourth quarter. Vident Advisory LLC now owns 14,392 shares of the specialty pharmaceutical company’s stock valued at $520,000 after buying an additional 309 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Supernus Pharmaceuticals by 2.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,664 shares of the specialty pharmaceutical company’s stock worth $480,000 after purchasing an additional 350 shares during the last quarter. Summit Investment Advisors Inc. raised its stake in shares of Supernus Pharmaceuticals by 7.6% in the fourth quarter. Summit Investment Advisors Inc. now owns 5,253 shares of the specialty pharmaceutical company’s stock worth $190,000 after purchasing an additional 369 shares during the last quarter. Bank of Montreal Can raised its stake in shares of Supernus Pharmaceuticals by 6.6% in the fourth quarter. Bank of Montreal Can now owns 7,595 shares of the specialty pharmaceutical company’s stock worth $275,000 after purchasing an additional 473 shares during the last quarter. Finally, Raiffeisen Bank International AG purchased a new position in shares of Supernus Pharmaceuticals in the fourth quarter worth $25,000.

Wall Street Analysts Forecast Growth

SUPN has been the subject of several recent analyst reports. Cantor Fitzgerald boosted their price target on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 6th. Wall Street Zen upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd.

Supernus Pharmaceuticals Price Performance

SUPN stock opened at $42.17 on Friday. The stock has a market capitalization of $2.36 billion, a P/E ratio of 36.67 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a 1-year low of $29.16 and a 1-year high of $43.62. The business has a fifty day moving average price of $34.19 and a 200-day moving average price of $33.55.

Insider Buying and Selling

In related news, CEO Jack A. Khattar sold 140,000 shares of the company’s stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $42.02, for a total transaction of $5,882,800.00. Following the completion of the sale, the chief executive officer owned 1,030,183 shares in the company, valued at approximately $43,288,289.66. This represents a 11.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 8.80% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.